Showing results (121-130 of 155) with videos related to
Sort By:
Pageof 16
Hepatology International|July 24, 2015
Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysisI-Cheng Lee, Teh-Ia Huo, Yi-Hsiang Huang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
The -251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese populationWei-Ping Lee, Dar-In Tai, Keng-Hsin Lan, et al.Journal of Gastroenterology|June 19, 2012
Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumorsMing-Huang Chen, Yi-Chen Yeh, Yi-Ming Shyr, et al.International Journal of Biological Sciences|December 21, 2016
Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumorsWen-Chi Chou, Po-Han Lin, Yi-Chen Yeh, et al.Journal of the Chinese Medical Association : JCMA|March 13, 2024
Feasibility estimation of injected hydrodissection before definitive radiotherapy of pancreatic adenocarcinomaYuan-Hung Wu, Shu-Huei Shen, Yen-Po Wang, et al.Cancer Science|December 3, 2019
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 studyYung-Jue Bang, Chung-Pin Li, Kyung-Hun Lee, et al.International Journal of Environmental Research and Public Health|January 11, 2022
The Impact of COVID-19 Pandemic on the Learning Outcomes of Medical Students in Taiwan: A Two-Year Prospective Cohort Study of OSCE PerformanceTzyy-Yurn Tzeng, Chia-An Hsu, Ying-Ying Yang, et al.Therapeutic Advances in Medical Oncology|November 25, 2021
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based studyTai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, et al.European Journal of Cancer (Oxford, England : 1990)|January 23, 2026
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)Nai-Jung Chiang, Yung-Yeh Su, I-Wei Ho, et al.The Oncologist|April 22, 2025
Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumorsNai-Jung Chiang, Jih-Hsiang Lee, Ming-Huang Chen, et al.Pageof 16